There you go, agreement confirmed. Life is good.
ASX RELEASE 28 June 2021
AMPLIA AND GARVAN INSTITUTE ENTER INTO COLLABORATION AGREEMENT
Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), a
company developing new approaches for the treatment for cancer and fibrosis, is pleased to announce
it has now finalised and executed a Collaboration Agreement and a Research & Licence Agreement
with the Garvan Institute of Medical Research (“Garvan”) in Sydney, Australia that was announced in
March 2021. These Agreements define the structure of an ongoing collaborative research and clinical
development program to be undertaken with Garvan which initially focuses on the use of Amplia’s FAK
inhibitor, AMP945, to treat patients with pancreatic cancer.
The collaboration, which was forecast with the signing of a non-binding Term Sheet in March 2021,
provides Amplia with access to Garvan’s research strength in FAK biology and its extensive clinical
research network. Already, non-clinical studies conducted in the laboratory of Professor Paul Timpson,
Cancer Research Theme Leader at Garvan, a world-renowned expert in FAK biology, have provided
Amplia with valuable insights into the ability of AMP945 to inhibit fibrosis and significantly improve
survival in an animal model of aggressive pancreatic cancer. The Company is incorporating these
insights and using its access to Garvan’s clinical research network to assist with the design and planning
of a Phase 2 clinical trial of AMP945 in patients with pancreatic cancer that is scheduled to commence
later this year. The terms of the final Collaboration Agreement also provide for expansion into other
therapeutic areas.
Amplia’s CEO and Managing Director, Dr John Lambert, commented that “It is very exciting for Amplia
to be able to tap into the extensive experience in FAK biology, cancer biology, and clinical networks
that are available at a globally-recognised research institute such as Garvan. We have already seen the
benefits of this collaboration through the results of the non-clinical studies which we announced
earlier this year. These studies have provided important insights into the biology of AMP945 and have
further validated our decision to progress this promising drug into a Phase 2 clinical trial in pancreatic
cancer patients.”
Professor Chris Goodnow, Garvan’s Executive Director noted that “At Garvan, we aim to translate our
cancer research findings into better treatment options and improved clinical outcomes for patients.
We are delighted to be working with Amplia in the development of its unique FAK inhibitors as
potential new anti-fibrotic treatments for patients with pancreatic cancer or other fibrotic diseases.”
Under the terms of the Collaboration Agreement, which has an initial term of 2 years, Amplia will
receive first rights to participate in research projects relating to the use of FAK inhibitors in
combination with other therapeutic products for the treatment of cancer. Under the terms of the
Research and Licence Agreement, Amplia agrees to fund studies of the use of AMP945 in combination
with gemcitabine / Abraxane® for the treatment of cancer, with an initial focus on pancreatic cancer,
and Amplia will receive first rights to new intellectual property arising from the collaboration.
This ASX announcement was approved and authorised for release by the Board of Amplia
Therapeutics.
- End
- Forums
- ASX - By Stock
- ATX
- Ann: AMP945 Improves Survival in Pacnreatic Cancer Model
Ann: AMP945 Improves Survival in Pacnreatic Cancer Model, page-50
Featured News
Add ATX (ASX) to my watchlist
|
|||||
Last
6.2¢ |
Change
0.001(1.64%) |
Mkt cap ! $16.84M |
Open | High | Low | Value | Volume |
6.1¢ | 6.4¢ | 6.1¢ | $2.155K | 35.07K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 59863 | 6.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.2¢ | 67722 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 59863 | 0.061 |
1 | 6169 | 0.060 |
2 | 93326 | 0.059 |
1 | 85991 | 0.058 |
1 | 42105 | 0.057 |
Price($) | Vol. | No. |
---|---|---|
0.067 | 117890 | 1 |
0.070 | 6009 | 1 |
0.074 | 73026 | 1 |
0.075 | 335646 | 1 |
0.081 | 100000 | 1 |
Last trade - 15.45pm 28/06/2024 (20 minute delay) ? |
Featured News
ATX (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online